Organisation paid for research Program year 2024 Source: CMS Open Payments

Lakes Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,894,401

1,071 payments

Through program year 2024, Lakes Research LLC is reported as receiving $2,894,401 in research payments, across 1,071 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$75,767	29
2023	Research	$239,533	121
2022	Research	$936,877	228
2021	Research	$453,645	241
2020	Research	$638,334	276
2019	Research	$550,244	176

Breakdown

Who paid Research payments · program years 2019–2024

AbbVie, Inc. $1,119,058 612 payments
Merck Sharp & Dohme Corporation $786,948 22 payments
GlaxoSmithKline, LLC. $493,196 318 payments
Eli Lilly and Company $284,946 33 payments
Pfizer Inc. $89,299 28 payments
Radius Health, Inc. $32,955 31 payments
Regeneron Pharmaceuticals, Inc. $30,778 11 payments
Spectrum Pharmaceuticals Inc. $15,197 1 payment
Veru Inc. $13,750 2 payments
Ucb SA $12,981 3 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $396,961 7 payments
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $274,775 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $224,970 10 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $184,933 76 payments
M14-465 $180,540 108 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $172,559 179 payments
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate $166,795 95 payments
A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $129,237 62 payments
M18-891 $111,883 37 payments
M13-542 $104,530 68 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.